Compare Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 vs GeneDx Holdings Corp — how do they compare? Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $46.65, while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| USOI | WGS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $61.17 | $167.51 |
52-Week Low | $42.27 | $34.51 |
Market Cap | — | $2.56B |
Enterprise Value | — | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USOI trades at $46.21 with a modest 0.26% daily gain, showing bullish technical momentum with moving averages supporting upward movement. The stock lacks traditional fundamental metrics as it represents an exchange-traded product tracking the Credit Suisse X-Links Crude Oil Shares Covered Call ETN. Recent market commentary highlights dividend growth strategies as potential opportunities in 2026.
The ETN structure presents unique risks including credit risk of the issuer and oil price volatility. Technical indicators suggest near-term strength but overbought conditions warrant caution. Investors should consider the product's specialized nature and correlation to energy markets when evaluating position sizing.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
